Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Branko Simic

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Current Vascular Pharmacology|December 25, 2012
Therapeutic targets to raise HDL in patients at risk or with coronary artery diseaseThomas F Lüscher, Arnold von Eckardstein, Branko Simic
Molecular Pharmaceutics|April 18, 2022
Sortase-Mediated Site-Specific Conjugation and <sup>89</sup>Zr-Radiolabeling of Designed Ankyrin Repeat Proteins for PETRachael Fay, Imre Törő, Anna-Lena Schinke, et al.
European Heart Journal|September 17, 2011
Torcetrapib impairs endothelial function in hypertensionBranko Simic, Matthias Hermann, Sidney G Shaw, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 18, 2021
The SHREAD gene therapy platform for paracrine delivery improves tumor localization and intratumoral effects of a clinical antibodySheena N Smith, Rajib Schubert, Branko Simic, et al.
Communications Biology|April 4, 2023
CRISPR-clear imaging of melanin-rich B16-derived solid tumorsRajib Schubert, Taegeun Bae, Branko Simic, et al.
Hypertension (Dallas, Tex. : 1979)|May 21, 2014
Adaptor protein p66(Shc) mediates hypertension-associated, cyclic stretch-dependent, endothelial damageRemo D Spescha, Martina Glanzmann, Branko Simic, et al.
Atherosclerosis|June 24, 2020
The NO-donor MPC-1011 stimulates angiogenesis and arteriogenesis and improves hindlimb ischemia via a cGMP-dependent pathway involving VEGF and SDF-1αBrigida Gomes de Almeida Schirmer, Margot Crucet, Simona Stivala, et al.
Atherosclerosis|February 3, 2017
Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increaseBranko Simic, Pavani Mocharla, Margot Crucet, et al.
European Heart Journal|August 22, 2014
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatinSusan Kühnast, Sam J L van der Tuin, José W A van der Hoorn, et al.
Cardiovascular Research|January 23, 2021
TNFα induces endothelial dysfunction in rheumatoid arthritis via LOX-1 and arginase 2: reversal by monoclonal TNFα antibodiesAlexander Akhmedov, Margot Crucet, Branko Simic, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Current Vascular Pharmacology|December 25, 2012
Therapeutic targets to raise HDL in patients at risk or with coronary artery diseaseThomas F Lüscher, Arnold von Eckardstein, Branko Simic
Molecular Pharmaceutics|April 18, 2022
Sortase-Mediated Site-Specific Conjugation and <sup>89</sup>Zr-Radiolabeling of Designed Ankyrin Repeat Proteins for PETRachael Fay, Imre Törő, Anna-Lena Schinke, et al.
European Heart Journal|September 17, 2011
Torcetrapib impairs endothelial function in hypertensionBranko Simic, Matthias Hermann, Sidney G Shaw, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 18, 2021
The SHREAD gene therapy platform for paracrine delivery improves tumor localization and intratumoral effects of a clinical antibodySheena N Smith, Rajib Schubert, Branko Simic, et al.
Communications Biology|April 4, 2023
CRISPR-clear imaging of melanin-rich B16-derived solid tumorsRajib Schubert, Taegeun Bae, Branko Simic, et al.
Hypertension (Dallas, Tex. : 1979)|May 21, 2014
Adaptor protein p66(Shc) mediates hypertension-associated, cyclic stretch-dependent, endothelial damageRemo D Spescha, Martina Glanzmann, Branko Simic, et al.
Atherosclerosis|June 24, 2020
The NO-donor MPC-1011 stimulates angiogenesis and arteriogenesis and improves hindlimb ischemia via a cGMP-dependent pathway involving VEGF and SDF-1αBrigida Gomes de Almeida Schirmer, Margot Crucet, Simona Stivala, et al.
Atherosclerosis|February 3, 2017
Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increaseBranko Simic, Pavani Mocharla, Margot Crucet, et al.
European Heart Journal|August 22, 2014
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatinSusan Kühnast, Sam J L van der Tuin, José W A van der Hoorn, et al.
Cardiovascular Research|January 23, 2021
TNFα induces endothelial dysfunction in rheumatoid arthritis via LOX-1 and arginase 2: reversal by monoclonal TNFα antibodiesAlexander Akhmedov, Margot Crucet, Branko Simic, et al.
Pageof 1